Recently Released Market Study: Human Papilloma Virus Partnering 2007-2013

Boston, MA -- (SBWire) -- 10/01/2013 --The Human Papilloma Virus Partnering 2007-2013 report provides understanding and access to the human papilloma virus partnering deals and agreements entered into by the worlds leading healthcare companies.

- Trends in human papilloma virus partnering deals
- Top human papilloma virus deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type

The Human Papilloma Virus Partnering 2007-2013 provides understanding and access to the human papilloma virus partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of human papilloma virus partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors human papilloma virus technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

View Full Report Details and Table of Contents

This data driven report contains over 70 links to online copies of actual human papilloma virus deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of human papilloma virus partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in human papilloma virus partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading human papilloma virus deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Human Papillomavirus Infections - Pipeline Review, H1 2013
- EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022
- Human Genome Sciences, Inc. - Product Pipeline Review - 2012
- Human Genome Sciences, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- DiaSorin Ireland Ltd - Product Pipeline Analysis, 2013 Update
- Herpes Infections - Pipeline Review, H1 2013
- Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2013
- Virax Holdings Limited (VHL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2013
- Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2013